Genomics plc is an ambitious genome analytics business formed in 2014 by four leading scientists at the University of Oxford: Peter Donnelly (Director of the Wellcome Trust Centre for Human Genetics), Gil McVean (Director of the Big Data Institute), Gerton Lunter, and Chris Spencer. There will be an explosion in human genomic data linked to health and other phenotypic outcomes and the company’s vision is to bring together this data and develop sophisticated analytical methods for its interpretation in various scientific contexts. We have already developed the largest genotype-phenotype database of its kind in the world (comprising 500 studies, almost 3 million participants and 400 unique phenotypes), together with functional genomic data. We are developing an integrated platform of genomic analysis tools which we will use across the healthcare industry, from pharmaceutical drug development to clinical decision-making. In the pharma space there is now clear evidence that human genetic evidence can be transformative for the success of drug development pipelines. We are currently working in collaboration with four major pharmaceutical companies and are looking to extend the range and number of these collaborations. Backed by some of the leading investors in life sciences, Genomics plc now has a cross-disciplinary team comprising over 40 scientists and software engineers, based in central Oxford.